Symposium | Comparing treatment options for patients with FLT3-ITD and -TKD mutations

The AML Hub held a webinar on November 19, 2025, titled, Understanding the differences between FLT3-ITD and -TKD mutations in AML: Implications for clinical practice. Here, we share a presentation from the webinar by Jorge Cortes, Georgia Cancer Center, Augusta, US, discussing treatment options for patients with FLT3-ITD and -TKD mutations.

Cortes describes the mechanisms of action of Type I and Type II FLT3 inhibitors, followed by an overview of key efficacy and survival data from clinical trials of FLT3-targeted therapies.

This educational resource is independently supported by Daiichi Sankyo. All content was developed by SES in collaboration with an expert steering committee. Funders were allowed no influence on the content of this resource.

Hosted on Acast. See acast.com/privacy for more information.